Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide

K Kalman1, M W Pennington, M D Lanigan

  • 1Departments of Physiology & Biophysics, and Microbiology and Molecular Genetics, University of California, Irvine, California 92697-4560, USA.

The Journal of Biological Chemistry
|November 26, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of disorder-free localization using a (2+1)D lattice gauge theory on a quantum processor.

Science (New York, N.Y.)·2026
Same author

Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort.

Clinical lung cancer·2026
Same author

Robot-assisted MIS transiliac sacroiliac joint fusion: Technical note.

Neuro-Chirurgie·2025
Same author

Functional Connectivity Is Stronger Between Unisensory and Multisensory Regions for Nonsimultaneous Judgments of Visual-Tactile Stimuli.

Psychophysiology·2025
Same author

First Constraint on Atmospheric Millicharged Particles with the LUX-ZEPLIN Experiment.

Physical review letters·2025
Same author

New Constraints on Cosmic Ray-Boosted Dark Matter from the LUX-ZEPLIN Experiment.

Physical review letters·2025

A novel ShK peptide, ShK-Dap22, selectively blocks T-lymphocyte Kv1.3 channels. This potent immunosuppressant shows low toxicity, offering potential for treating autoimmune diseases and preventing graft rejection.

Area of Science:

  • Immunology
  • Molecular Pharmacology
  • Biochemistry

Background:

  • Kv1.3 channels are key targets for immunosuppression in T lymphocytes.
  • The sea anemone peptide ShK is a potent inhibitor of Kv1.3 and related potassium channels.

Purpose of the Study:

  • To determine the binding configuration of ShK to Kv1.3.
  • To engineer a more selective and potent Kv1.3 inhibitor.
  • To evaluate the therapeutic potential of the engineered peptide.

Main Methods:

  • Mutant cycle analysis and complementary mutagenesis of ShK and Kv1.3.
  • Structural analysis using Nuclear Magnetic Resonance (NMR).
  • In vitro T-lymphocyte proliferation assays and in vivo toxicity studies.

Related Experiment Videos

Main Results:

  • A likely docking model for ShK in Kv1.3 was established.
  • ShK-Dap22, a modified ShK peptide, demonstrated high selectivity and potency against Kv1.3.
  • ShK-Dap22 suppressed T-lymphocyte activation in vitro and exhibited low toxicity in vivo.

Conclusions:

  • ShK-Dap22 is a potent and selective Kv1.3 channel blocker.
  • The modified peptide shows promise as an immunosuppressant for autoimmune diseases and transplant rejection.
  • Further development of ShK-Dap22 or analogues is warranted for clinical applications.